LONGBOARD PHARMACEUTICALS, INC.

(LBPH)
  Report
Delayed Nasdaq  -  05/13 03:53:07 pm EDT
4.500 USD   -3.23%
05/12Longboard Pharmaceuticals to Participate in Upcoming Investor Events
AQ
05/06Wedbush Cuts Price Target on Longboard Pharmaceuticals to $12 From $14 'on Lower Net Cash;' Outperform Rating Kept
MT
05/05LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Longboard Pharmaceuticals : Posts Q2 Loss

08/09/2021 | 11:57am EDT


ę MT Newswires 2021
All news about LONGBOARD PHARMACEUTICALS, INC.
05/12Longboard Pharmaceuticals to Participate in Upcoming Investor Events
AQ
05/06Wedbush Cuts Price Target on Longboard Pharmaceuticals to $12 From $14 'on Lower Net Ca..
MT
05/05LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
05/05Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/05Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Fina..
AQ
04/27HC Wainwright Initiates Longboard Pharmaceuticals at Buy with $25 Price Target
MT
04/01Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of ..
AQ
03/23Longboard Pharmaceuticals to Participate in Cantor Fitzgerald's Virtual Rare Orphan Dis..
AQ
03/22Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference
AQ
03/22Longboard Pharmaceuticals Names Industry Veteran Randall Kaye as CMO
MT
More news
Analyst Recommendations on LONGBOARD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -40,3 M - -
Net cash 2022 70,0 M - -
P/E ratio 2022 -2,04x
Yield 2022 -
Capitalization 77,5 M 77,5 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 22
Free-Float 53,8%
Chart LONGBOARD PHARMACEUTICALS, INC.
Duration : Period :
Longboard Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONGBOARD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 4,50 $
Average target price 19,74 $
Spread / Average Target 339%
EPS Revisions
Managers and Directors
Kevin R. Lind President, CEO, Secretary & Director
Brandi L. Roberts Chief Financial Officer
Paul Jai Sekhri Chairman
Randall E. Kaye Chief Medical Officer
Chadwick J. Orevillo Vice President & Head-Operations
Sector and Competitors
1st jan.Capi. (M$)
LONGBOARD PHARMACEUTICALS, INC.-7.79%77
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601